THE EFFECT OF CANDESARTAN PRE-STROKE USE ON THE FUNCTIONAL OUTCOME OF POST ISCHEMIC STROKE PATIENTS IN BETHESDA HOSPITAL YOGYAKARTA by Gulo, Lise Insani et al.
JURNAL FARMASI SAINS DAN KOMUNITAS, May 2018, 37-46  Vol. 15 No. 1 
p-ISSN 1693-5683; e-ISSN 2527-7146 
doi: http://dx.doi.org/10.24071/jpsc.151660   
 
*Corresponding author: Lise Insani Gulo 
Email: gliseinsani@gmail.com 
THE EFFECT OF CANDESARTAN PRE-STROKE USE ON THE FUNCTIONAL 
OUTCOME OF POST ISCHEMIC STROKE PATIENTS IN BETHESDA HOSPITAL 
YOGYAKARTA 
 
PENGARUH RIWAYAT TERAPI CANDESARTAN PRASTROKE TERHADAP 
LUARAN FUNGSIONAL PASIEN STROKE ISKEMIK DI RUMAH SAKIT BETHESDA 
YOGYAKARTA 
 
Lise Insani Gulo1*), Rizaldy Taslim Pinzon2, Esdras Ardi Pramudita3 
1Faculty of Medicine Duta Wacana Christian University Yogyakarta, JL. DR. Wahidin 
Sudirohusodo 5-25 Yogyakarta 55224, Daerah Istimewa Yogyakarta 
2Bethesda Hospital Yogyakarta, Jalan Jendral Sudirman No. 70, Kotabaru, Gondokusuman, Kota 
Yogyakarta, Daerah Istimewa Yogyakarta 
3Panti Rapih Hospital, Jl. Cik Di Tiro No.30, Caturtunggal, Kec. Depok, Kabupaten Sleman 
55223, Daerah Istimewa Yogyakarta 
 
Received September 11, 2017; Accepted March 2, 2018 
 
 
ABSTRACT 
Stroke is a leading cause of death and disability, where the main risk factor is hypertension. 
Angiotensin Receptor Blocker (ARB) is the most common drug for stroke prevention in high-risk 
hypertensive patients. The purpose of this study was to see whether the candesartan pre-stroke use 
can improve the functional outcomes of post ischemic stroke patients. The data were obtained 
from 191 retrospective observational studies. Data were collected from Stroke Registry and 
medical record at Bethesda Hospital Yogyakarta in 2014-2016, then analyzed univariate, 
followed by bivariate analysis using chi-square test, independent t-test and fisher exact test for the 
variable which has actual count (F0), and logistic regression for multivariate analysis. One 
hundred and ninety one samples were systematically reviewed to evaluate the effect of 
candesartan pre-stroke use on functional outcomes of post ischemic stroke patients in Bethesda 
hospital Yogyakarta whose range of ages was mostly between 61 and 70 years (30.9%) and were 
mostly male patients (56.5%). Patients with good functional outcomes (<2) were 79.6% and poor 
functional outcomes (≥2) were 20.4%. The results of bivariate analysis showed that candesartan 
did not affect the improvement of clinical outcome (OR: 1.806, 95% CI: 0.591-5.519, p: 0.294), 
and also not better than other angiotensin receptor blocker (p=0.505, OR=1.472, 95% CI= 
0.470-4.611). The multivariate analysis showed that sex (OR: 0.366, 95% CI: 0.156-0.858, p: 
0.021), loss of consciousness (OR: 0.107, 95% CI: 0.021-0.549, p: 0.007), limb weakness (OR: 
0.236, 95% CI: 0.067-0.834, p: 0.025), dyslipidemia comorbidity (OR: 2.750, 95% CI: 1.177-
6.427, p: 0.019) and aphasia (OR: 0.342, 95% CI: 0.107-1.100, p: 0.072) affected the functional 
outcome. The candesartan pre-stroke use did not improve the functional outcome of post ischemic 
stroke patient. 
Keywords: angiotensin receptor blocker, candesartan, functional outcome, ischemic stroke, 
neuron protection 
ABSTRAK 
Stroke merupakan masalah neurologis yang menyebabkan kecacatan serta kematian yang 
tinggi, dimana faktor utama penyebabnya adalah hipertensi. Angiotensin Receptor Blocker (ARB) 
adalah salah satu obat pilihan utama untuk prevensi stroke pada pasien hipertensi. Tujuan 
dilakukannya penelitian ini adalah untuk melihat apakah riwayat terapi candesartan prastroke 
dapat memperbaiki luaran fungsional pasien paska stroke iskemik. Penelitian ini dilaksanakan 
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dengan menggunakan metode kohort retrospektif. Data diambil dari Stroke Registry dan rekam 
medis di Rumah Sakit Bethesda Yogyakarta pada tahun 2014-2016, kemudian dianalisis secara 
univariat, dilanjutkan analisis bivariat menggunakan uji chi-square test, uji-t independen dan uji 
fisher exact pada variabel yang memiliki actual count (F0), serta regresi logistik untuk analisis 
multivariat. Total jumlah sampel yang diambil pada penelitian adalah sebanyak 191 sampel 
dengan proporsi rentang usia terbanyak 61-70 tahun (30.9%) dan berjenis kelamin laki-laki 
(56.5%). Pasien dengan luaran fungsional baik (<2) adalah 79.6% dan luaran fungsional buruk 
(≥2) sebanyak 20.4%. Analisis bivariat menunjukkan bahwa candesartan tidak mempengaruh 
perbaikan luaran fungsional pasien (OR:1.806, 95%CI:0.591-5.519, p:0.294) dan tidak lebih baik 
daripada obat ARB yang lain (p=0.505, OR=1.472, 95% CI= 0.470-4.611). Hasil multivariat 
menyatakan jenis kelamin (OR:0.366, 95%CI:0.156-0.858, p:0.021), penurunan kesadaran 
(OR:0.107, 95%CI:0.021-0.549, p:0.007), kelemahan anggota gerak (OR:0.236, 95%CI:0.067-
0.834, p:0.025), komorbid dislipidemia (OR:2.750, 95%CI:1.177-6.427, p:0.019) dan afasia 
(OR:0.342, 95%CI:0.107-1.100, p:0.072) mempengaruhi luaran fungsional pasien.  Riwayat 
terapi candesartan prastroke tidak memperbaiki luaran fungsional pasien setelah stroke.  
 
Kata kunci: angiotensin receptor blocker, candesartan, luaran fungsional, stroke iskemik,  
proteksi neuron 
 
 
 
INTRODUCTION 
Stroke is a neurological problem that 
causes disability and death and ranks as the 
first cause of deaths in Indonesia (CDC, 
2016). Subarachnoid hemorrhage strokes are 
found on 1.4% of patients, intracerebral 
hemorrhage strokes are found on 18.5% of 
patients, and ischemic strokes are found on 
42.9% of patients (Kusuima, 2009). 
Hypertension is one of the main risk factors 
that a person may experience a stroke, 
specifically in the Special Region of 
Yogyakarta, the number of hypertension 
increases from 8.3% in 2007 to 12.8% in 
2013. Therefore, to control hypertension is 
needed to prevent the incidence of stroke 
(Yastroki, 2016; Riset Kesehatan Dasar, 
2013). The effects of several anti-hypertension 
options are more than simply lowering down 
the blood pressure, such as ARB which 
protects the brain by its mechanism to lower 
the blood pressure, but also by the AT 2 
receptor’s improved performance which 
occurred due to the blockade of AT 1 receptor.  
Angiotensin receptor blockers have been 
examined to have anti-inflammatory effects on 
the brain that mostly occur in the stroke 
patients, the two main processes that cause 
brain inflammation are peripheral infection 
and direct cell injury as a consequence of 
metabolic changes in the brain parenchyma 
while the presence of ischemia, however, in 
each ARB drug option is believed to have 
different efficacy in reducing the brain 
inflammatory of the ischemic stroke patients. 
Candesartan is one of the ARB drug options 
that is still controversial in recovering the 
functional outcomes of the ischemic stroke 
patients so that the researchers are keen to 
assess whether candesartan is able to improve 
the functional outcomes of the post ischemic 
stroke patients (Chrysant and Chrysant, 2006; 
Tziomalos et al., 2014). 
 
METHODS 
The research was carried out at the 
Bethesda Hospital, Yogyakarta, starting from 
February to April 2017, by using the 
retrospective cohort study as the method. 
Ischemic stroke patients were divided into two 
main groups namely the group of patients with 
the record of using pre-stroke candesartan and 
the group of patients with the record of using 
other anti-hypertension besides candesartan. 
The selection of the patients was conducted by 
using the purposive sampling technique in 
accordance with the existing criteria of 
inclusion and exclusion. The selected samples 
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were the patients who had been diagnosed 
using the cranial CT scan; who had the results 
of modified ranking scale (mRS) upon 
discharge; who had experienced the primer 
stroke onset and at the onset of less than 24 
hours when hospitalized; and whose record of 
patients’ data showed that they used 
angiotensin receptor blocker (ARB) type of 
anti-hypertension before the stroke onset, 
which was taken and then a sub-analysis was 
conducted to assess whether the candesartan 
was better than the other ARB drug choices. 
The patients who returned home at their own 
request, referral patients, and patients with 
incomplete medical record, were not taken as 
samples.   
The research was conducted by using the 
instruments, such as patients’ data forms and 
stroke registry with a minimum 53 samples 
per group. However, after the research was 
running, the comparison was altered into 1:4 
so that the minimum number of the 
candesartan group was 21 patients and non-
candesartan of anti-hypertension group was 85 
patients (Sullivan and Soe, 2007). Then, the 
obtained samples were analyzed using 
univariate analysis in order to look at the 
samples’ characteristics, followed by a 
bivariate analysis and then multivariate 
analysis to look at which variables that 
affected the patients’ functional outcome 
significantly.  
The data processing was conducted in 
the Clinical Epidemiology and Biostatistics 
Unit (CE&BU) Faculty of Medicine Gadjah 
Mada University by firstly taking the samples 
based on the criteria of inclusion i.e. all 
ischemic stroke patients diagnosed by using 
cranial CT scan and having the mRS results 
upon discharge so that the patients who were 
forced to discharge were excluded from the 
research. The selected patients had to have a 
candesartan therapy record and other pre-
stroke hypertension and had experienced 
primer stroke with the onset of less than 24 
hours. The referral patients from other 
hospitals, patients having incomplete medical 
data record, and those who were not recorded 
in the registry data had been excluded from 
the research. 
RESULTS AND DISCUSSION 
There were 191 samples analyzed by 
using a descriptive, bivariate and multivariate 
analysis. Based on Table I, the data of patients 
with a good functional outcome (mRS<2) was 
obtained, as much as 79.6% (152 samples) and 
a poor functional outcome (mRS ≥ 2) with the 
amount of 20.4% (39 samples) or 56.5% of 
male and 43.5% of female. The analysis was 
followed up by using a bivariate analysis and 
then multivariate analysis aimed to analyze the 
significance of the variables toward ischemic 
stroke patients’ functional outcome recovery. 
At this stage, the significance of the variables 
was seen from the value of p, if the value of 
p<0.05, the variables were declared 
significant. On the contrary, if the value of 
p>0.05, the variables were declared not 
significant. 
The total number of the samples taken 
in this research was 191 samples and as 
presented in Table I, it was seen that the 
incidence of stroke commonly occurred at the 
age between 61 and 70 years (30.9%), in 
which 56.5% of the patients were male. The 
stroke onset events were mostly at the duration 
of 3-6 hours (31.9%) and 93.7% of the total 
samples did not experience loss of 
consciousness, 170 samples (89%) 
experienced aphasia and 144 samples (75.4%) 
experienced limb weakness. The patients 
having dyslipidemia comorbidities (52.9%) 
were more than those having comorbidities of 
atrial fibrillation (3.1%), while the total 
number of the patients experiencing 
complications was 83 samples (43.5%), the 
number of patients having complications on 
urinary tract infection and decubitus was 2 
samples (1%) of the total samples on each 
category. The total number of patients who got 
neuroprotection therapy was 37.7% of the total 
samples and the patients with a record of using 
pre-stroke candesartan were to 15.7%, while 
the percentage of patients recorded to have 
used other anti-hypertension was 89.5% in 
which the sub-analysis was conducted to those 
two groups on the patients with a record of 
using only ARB drugs and then compared to 
the other ARBs to assess whether candesartan 
was a better choice than the other ARBs. 
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Table I. Basic Characteristics of the Research Subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on Table II, some variables that 
were considered significant were the gender 
(p:0.028), loss of consciousness (p:0.000), 
aphasia (p:0.007), limb weakness (p:0.020), 
dyslipidemia comorbidities (p:0.002), 
decubitus complication (p:0.005) by using 
fisher’s exact test, the duration of 
hospitalization (p:0.023), meanwhile the 
record of candesartan therapy as a free 
variable in this study showed the results of 
The Characteristics of the Patients n= 191 (%) 
Ages 
< 40 years old 
40-50 years old 
51-60 years old 
61-70 years old 
>70 years old 
Gender 
Female 
Male 
Candesartan 
Yes 
No 
Anti-hypertension non- candesartan 
Yes 
No 
mRS Nominal 
good mRS 
bad mRS  
Onset  
<3 hours 
3-6 hours 
6-12 hours 
12-24 hours 
>24 hours 
Loss of Consciousness 
Yes 
No 
Aphasia  
Yes 
No 
Limbs weakness  
Yes 
No 
Dyslipidemia Comorbidities  
Yes 
No 
Comorbidities of Atrial Fibrillation 
Yes 
No 
Complications 
Yes 
No 
Urinary Tract Infection Complications  
Yes 
No 
Decubitus Complications  
Yes 
No 
Neuroprotection  
Yes 
No 
Hospitalization Duration  
     >5 days 
≤5 days 
 
2 
32 
56 
59 
42 
 
83 
108 
 
30 
161 
 
171 
20 
 
152 
39 
 
34 
61 
49 
47 
0 
 
12 
179 
 
21 
170 
 
144 
47 
 
101 
90 
 
6 
185 
 
83 
108 
 
2 
189 
 
2 
189 
 
72 
119 
 
82 
109 
 
1.0 
16.8 
29.3 
30.9 
22.0 
 
43.5 
56.5 
 
15.7 
84.3 
 
89.5 
10.5 
 
79.6 
20.4 
 
17.8 
31.9 
25.7 
24.6 
0 
 
6.3 
93.7 
 
11.0 
89.0 
 
75.4 
24.6 
 
52.9 
47.1 
 
3.1 
96.9 
 
43.5 
56.5 
 
1.0 
99.0 
 
1.0 
99.0 
 
37.7 
62.3 
 
42.9 
57.1 
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being not significant (p:0.294, OR: 1.806, 
95%CI:0.591-5.519), as in other anti-
hypertension types (p:0.961, OR: 0.971, 
95%CI:0.305-3.089). Moreover, the sub-
analysis was performed in the patients with a 
history of using only ARB therapy to assess 
whether the candesartan gave a better result of 
functional recovery compared to the other 
ARB medication choices and the results of the 
analysis in Table III showed that candesartan 
was not better than other ARB medication 
options (p:0.505, OR:1.472,95%CI:0.470-
4.611). 
Invalidity of a history on the use of ARB 
in patients’ functional recovery was in line 
with the research conducted by Sandset et al. 
in 2011 involving 2029 patients from 146 
centers in nine Northern European countries in 
a cohort prospective study. This study stated 
that the analysis of the functional outcome 
referred to the risk of a poor functional 
outcome on the given candesartan group (p: 
0.048, OR:1.17.95% CI:1.00-1.38), the 
researchers even stated that 2% of the total 
patients experienced hypotension and renal 
failure, in which this value is bigger compared 
to the placebo group that is only 1% (Sanset et 
al., 2011).  
The activation of central angiotensin II 
triggered a cerebral ischemia event. When the 
angiotensin II bound up with AT1 receptor, 
there would be a sympathetic effect triggered 
as the occurrence of vasoconstriction, the 
proliferation of cells and the other AT1 
receptor effects, so the use of candesartan 
would help restore the blood flow during the 
ischemia that the cerebrovascular auto-
regulation process with a specific blockade on 
AT1 receptor became an important mechanism 
for the brain protection. However, the 
effectiveness of candesartan in recovering the 
functional for pre-therapy ischemic stroke 
patients was highly influenced by the state of 
blood-brain barrier on each patient. As 
described by Pelisch et al. (2010), candesartan 
had a limitation in penetrating the blood-brain 
barrier that was highly dependent on the dose, 
at the time allotment and liposoluble 
compounds, whereas the hypertension 
potentially caused cerebral ischemia and, on 
such circumstances, the angiotensin II was 
found that worsening the state due to 
unavoidable AT1 receptor activation (Pelisch 
et al., 2010). Candesartan itself had a low 
bioavailability, i.e. 40%, and it would be 
eliminated once it was injected to the blood 
systemic circulation mainly in the kidneys. 
The effective use of candesartan clinical dose 
ranged between 8 up to 32 mg per day, in 
which the monotherapeutic response levels of 
candesartan would rise up as the dose 
increased, but the absorption of candesartan 
never exceeded 60% so this would affect the 
efficacy of candesartan in pre-stroke therapy 
(Seltzer et al., 2004). 
 
 
Table II. Predictive Factors of Functional Recovery of Ischemic Stroke Patients  
Variables mRS <2 (n=152) mRS ≥2 (n=39) OR 95% CI p  
Candesartan Record  
  
  
 
Yes 26 (13.6%) 4 (2.1%) 
1.806 
0.591- 
5.519 
0.294 
No 126 (66.0%) 35 (18.3%) 
  
 
Non- Candesartan Anti-hypertension Record 
  
  
 
Yes 136 (71.2%) 35 (18.3%) 
0.971 
0.305- 
3.089 
0.961 
No 16 (8.4%) 4 (2.1%) 
  
 
Age (years old) 
  
  
0.764 
<40 2 (1.0%) 0 (0.0%) Reff Reff 
 
40-50 27 (14.1%) 5 (2.6%) 1.56 0 – 23.56 
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51-60 45 (23.6%) 11 (5.8%) 1.28 0 – 16.27 
 
61-70 47 (24.6%) 12 (6.3%) 1.23 0 – 15.47 
 
>70 31 (16.2%) 11 (5.8%) 0,89 0 
 
Gender 
  
  
0.028 
Male 92 (48.2%) 16 (8.4%) 0.454 0.222-0.928 
 
Female 60 (31.4%) 23 (12.0%) 
   
Onset 
  
  
0.29 
< 3 hours 26 (13.6%) 8 (4.2%) Reff Reff  
 
3-6 hours 46 (24.1%) 15 (7.9%) 0.94 0.31 – 2.79 
 
6-12 hours 38 (19.9%) 11 (5.8%) 1.06 0.33 – 3.37 
 
12-24 hours 42 (22.0%) 5 (2.6%) 2.58 0.67 – 10.37 
 
Decreased of Consciousness  
  
  
<0.001 
Yes 4 (2.1%) 8 (4.2%) 0.105 0.030-0.370 
 
No 148 (77.5%) 31 (16.2%) 
   
Aphasia 
  
  
0.007 
Yes 12 (6.3%) 9 (4.7%) 0.286 0.111-0.739 
 
No 140 (73.3%) 30 (15.7%) 
   
Limbs Weakness  
  
  
0.02 
Yes 109 (57.1%) 35 (18.3%) 0.29 0.097-0.864 
 
No 43 (22.5%) 4 (2.1%) 
   
Dyslipidemia Comorbidities 
  
  
0.002 
Yes 89 (46.6%) 12 (6.3%) 3.179 1.497-6.747 
 
No 63 (33.0%) 27 (14.1%) 
   
Comorbidities Atrial Fibrillation 
  
  
0.425 
Yes 4 (2.1%) 2 (1.0%) 0.5 0.088-2.835 
 
No 148 (77.5%) 37 (19.4%) 
   
Complications 
  
  
0.985 
Yes 66 (34.6%) 17 (8.9%) 0.993 0.489-2.019 
 
No 86 (45.0%) 22 (11.5%) 
   
Urinary Tract Infection Complication 
  
  
0.297 
Yes 1 (0.5%) 1 (0.5%) 0.252 0.015-4.116 
 
No 151 (79.1%) 38 (19.9%) 
   
Decubitus Complications  
  
  
0.005 
Yes 0 (0.0%) 2 (1.0%) 0.08 0 - 0.93  
No 152 (79.6%) 37 (19.4%) Reff Reff 
 
Neuroprotection 
  
  
0.912 
Yes 57 (29.8%) 15 (7.9%) 0.96 0.465-1.980 
 
No 95 (49.7%) 24 (12.6%) 
   
Hospitalization Duration 
  
  
0.023 
>5 days 59 (30.9%) 23 (12.0%) 2.266 1.107-4.639 
 
≤5 days 93 (48.7%) 16 (8.4%) 
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Table III. Sub Analysis of Candesartan VS ARB Non- Candesartan 
Variables 
mRS <2 
(n=132) 
mRS ≥2 
(n=28) 
OR 95% CI p  
Record of ARB Non- Candesartan 106 (66.3%) 24 (15.0%) 1.472 0.470-4.611 0.505 
Record of Candesartan 26 (16.3%) 4 (2.5%) 
   
 
Table IV. Multivariate Analysis 
 
 
Sandset et al. (2015) stated that 
candesartan recovered the patients’ functional 
outcome, but its efficacy also depended on the 
type of sub-types of ischemic stroke 
experienced by the patients, in which a better 
functional outcome tended to occur on the 
patients with lesions on the myocardial 
infarction on the total anterior circulation 
infarction (TACI) sub type or on the partial 
anterior circulation infarction (PACI) sub type 
rather than on lacunar infarction (LACI) 
(p:0.02). Thus, the pre-stroke hypertension 
patients who started experiencing ischemic on 
the anterior circulation on either partial or total 
would be greatly helped with the use of 
candesartan because if there was a bigger 
infarction on TACI and PACI, the patients 
became vulnerable to the development of 
cerebral edema or the possibility of the 
hemorrhage occurrence. This type of 
infraction was more commonly caused by 
atherothrombotic or acrdioembolic that were 
supported by the prevalence of atrial 
fibrillation which was higher for the patients 
with this infarction sub type. Thus, it made 
sense if reducing the blood pressure on this 
sub type would avoid the risk, even though the 
candesartan in doing brain protection was not 
as simple as reducing the patients’ blood 
pressure. As explained in the previous chapter, 
the candesartan just blocked the AT1 receptor 
so it meant that AT2 receptor that had an 
opposite working mechanism would greatly 
help protect the brains. Most patients who 
experienced LACI were chronic hypertension 
sufferers who eventually showed an auto-
regulation ability in regulating brain blood 
regulation. It was believed that reducing the 
blood pressure would cause blood perfusion 
deficits broadly on the brain because the blood 
flow became inadequate in doing brain tissue 
perfusion (Sandset et al., 2015). On the other 
hand, these things were the reasons why the 
patients with the candesartan record did not 
show functional outcome improvement. In this 
research, the dose of therapy and the 
obedience of each patient could not be 
researched, as supported by the candesartan’s 
limitation in penetrating the blood-brain 
barrier and the wide ischemic that occurred 
when the patient experienced hypertension. 
The results of this study indicated that 
the male patients had lower functional 
outcome probability than female patients. This 
contrasted to the Ng et al. (2013) who stated 
that female patients had worse post-stroke 
physical ability than male patients who were 
able to do physical activity independently 
(HR: 0.51, 95%CI:0.32-0.79). The researcher 
stated that the pre-stroke physical function and 
Outcome 
OR 95% CI 
p  
 Lower Upper 
Gender 0.366 0.156 0.858 0.021 
Decrease of Consciousness 0.107 0.021 0.549 0.007 
Aphasia 0.342 0.107 1.100 0.072 
Limbs Weakness 0.236 0.067 0.834 0.025 
Dyslipdemia 2.750 1.177 6.427 0.019 
Duration of hospitalization 1.305 0.554 3.074 0.543 
Decubitus Comorbidities 0.000 0.000 - 0.999 
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the symptoms of depression were important 
factors in the different results of the both 
gender recovery (Ng et al., 2013). Some 
researches indicated that female experienced 
more severe stroke compared to male even 
though other studies indicated that there was 
no significant difference in both genders. The 
International Stroke Trial found that the 
incidence of death on female was high in 6 
months after the stroke. This was corroborated 
by Gargano and Reeves (2007) who agreed 
that female had lower functional outcome and 
a poor quality of life compared to male after a 
devastating stroke. Meanwhile, The Women’s 
Health Organization MONICA Project found 
that within 28 days of observation on ischemic 
stroke patients, the mortality rate of female 
was on par or higher than male. However, it 
was in contrast to the latest research from 
Framingham Heart Study which found that 
there was no significant difference on 
mortality of both genders. The fundamental 
difference between male and female such as 
age, comorbidity, severity, and pre-stroke 
disability commonly caused deaths on female, 
but even when these factors had been 
controlled, female still had worse functional 
outcome (Gargano and Reeves, 2007; Persky 
et al., 2010; Min et al., 2005). 
Patients who experienced aphasia 
independently had probability of having good 
functional outcome 0.342 times compared to 
those who did not experience it (0R:0.342), 
however, Maas et al. (2012) stated that the 
evaluation results of ischemic stroke patients 
who suffered aphasia after 6 months would 
have a recovery of 86% and 74% (Maas et al., 
2012). Based on the results of the multivariate 
analysis (Table IV), it was clearly presented 
that the patients entering the hospital with 
decreased consciousness had the probability of 
having worse functional outcome than those 
who did not experience it (OR:0.107), Tsao et 
al. (2005) in their study stated that the patients 
with a good level of consciousness during the 
attack was related with a good functional 
outcome of the patients (Tsao et al., 2005). 
The patients who enter the hospital with 
decreased consciousness described the stroke 
severity they experienced and the wider 
lesions, the more severe brain hypoxia 
occurred so that this would influence the 
extent of the penumbra that could be saved in 
order to get the patients a better functional 
outcome. 
Patients with dyslipidemia had the 2.75 
times probability of having a good functional 
outcome compared to those who did not 
experience it. Out of the patients with 
dyslipidemia comorbidities, 89 patients had a 
good functional outcome while 12 patients had 
a bad functional outcome. In the patients 
without comorbidities, there were 63 patients 
with a good functional outcome and 27 
patients with a bad functional outcome. A 
study on meta-analysis in 2007 stated that the 
total number of cholesterol did not take part 
significantly on the mortality of the ischemic 
stroke patients aged 40-59 years. However, it 
was strongly influenced by the patients’ blood 
pressure. For the patients with blood pressure 
more than 145 mmHg, their cholesterol did 
not strongly affect the patients’ mortality. It 
was estimated to be due to vascular collaterals 
on the brains, but a meta-analysis stated that 
decreasing the cholesterol levels might reduce 
the risk of stroke (Lewington et al., 2008). The 
multivariate analysis showed that the limb 
weakness was strongly affected by bad 
functional outcome (OR:0.236). Gray et al. 
(2012) stated that after a stroke, the patients 
would spend more than 50% of their time 
lying down. This inactivity caused sarcopenia 
to occur. Sarcopenia is the state in which the 
patients lose their muscle mass causing them 
to gain more fat mass in the body. Within 2 
weeks of inactivity, it had already caused the 
loss of muscle mass and its strength. Thus, the 
damage caused by stroke and immobility 
would simultaneously cause the loss of muscle 
mass and impact on the patients’ 
independence in doing physical activities 
(Gray et al., 2012). 
Long hospitalization did not improve 
the patients’ functional outcome. This finding 
was contradicted by Bindawas et al. (2016) 
who stated that patients who were hospitalized 
for a long time were closely related to 
comorbid disease that accompanied it. 
Therefore, it was common that the patients’ 
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functional outcome became worse, whereas 
the patients with a short and medium time of 
hospitalization had better functional outcome. 
In this state, the patients were considered as 
having an efficient medication so that they had 
shorter time of hospitalization. However, the 
decision regarding to the length of 
hospitalization extremely varied to adjust to 
the type of insurance service applied by the 
corresponding health services so that it was 
reasonable that the duration of hospitalization 
could not be a specific benchmark in 
determining the patients’ functional outcome 
when they were out of the hospital. The length 
of hospitalization could usually be prolonged 
under a certain condition of the patients. Wang 
et al. (2014) concluded that the patients who 
underwent a decubitus rehabilitation would 
experience motor skill declining and likely to 
enter into the community (Wang et al., 2014; 
Bindawas et al., 2016). 
 
CONCLUSION 
Based on the analysis and the discussion 
above, it is concluded that the use of 
candesartan therapy before the onset of stroke 
does not affect patients’ clinical improvement 
after a stroke. 
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